<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1810222758
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Koselugo
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SELUMETINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        19792.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Pharmaceuticals Inc. " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Pharmaceuticals Inc. 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca AB 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What Koselugo is and how it works</strong></p><p dir="ltr">Koselugo contains the active substance Selumetinib.</p><p dir="ltr">Selumetinib is a type of medicine called a MEK inhibitor. It works by blocking certain proteins involved in the growth of tumor cells.</p><p dir="ltr">Koselugo is expected to shrink tumors that grow along nerves, called plexiform neurofibromas. These tumors are caused by a genetic condition called neurofibromatosis type 1 (NF1).</p><p dir="ltr"><strong>What Koselugo is used for</strong></p><p dir="ltr">Koselugo is used to treat children aged 3 years and above with plexiform neurofibromas that cannot be completely removed by surgery.</p><p dir="ltr">If you have any questions about how Koselugo works or why this medicine has been prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Koselugo:</strong></p><ul dir="ltr"><li>if you are allergic to Selumetinib or any of the other ingredients of this medicine (listed in section 6)</li><li>if you have severe liver disease</li></ul><p dir="ltr">If you are not sure, talk to your doctor, pharmacist or nurse before taking Koselugo.</p><p dir="ltr"><strong>Warnings and precautions</strong></p><p dir="ltr">Talk to your doctor, pharmacist or nurse before and during your treatment with Koselugo:</p><ul dir="ltr" style="margin-right:40px"><li>if you have eye problems</li><li>if you have heart problems</li><li>if you have liver problems</li><li>if you take supplements containing vitamin E</li><li>if you cannot swallow the capsule whole</li></ul><p dir="ltr">If any of the above apply to you (or you are not sure) talk to your doctor, pharmacist or nurse before taking this medicine.</p><p dir="ltr"><strong>Eye problems</strong></p><p dir="ltr">Koselugo can cause eye problems (see section 4 &lsquo;Possible side effects&rsquo;). <strong>Tell your doctor straight away </strong>if you get blurred vision or any other changes to your sight during treatment. Your doctor should examine your eyes if you have any new or worsening problems with your sight while you are taking this medicine.</p><p dir="ltr"><strong>Heart problems</strong></p><p dir="ltr">Koselugo can lower the amount of blood pumped by your heart (see section 4 &lsquo;Possible side-effects&rsquo;). Your doctor will check how well your heart works before and during your treatment with Koselugo.</p><p dir="ltr"><strong>Liver problems</strong></p><p dir="ltr">Koselugo can increase the amount of some liver enzymes in your blood (see section 4 &lsquo;Possible side effects&rsquo;). Your doctor will do blood tests before and during treatment to check how well your liver is working.</p><p dir="ltr"><strong>Supplemental vitamin E</strong></p><p dir="ltr">Koselugo capsules contain vitamin E that may increase your risk of bleeding. This means you should tell your doctor if you take other medicines that increase your risk of bleeding such as:</p><ul dir="ltr" style="margin-right:40px"><li>acetylsalicylic acid (also known as aspirin) for pain and inflammation</li><li>anticoagulant medicines (blood thinners) such as warfarin or other medicines used for preventing blood clots</li><li>supplements that may increase your risk of bleeding, such as vitamin E</li></ul><p dir="ltr"><strong>Difficulty swallowing capsules</strong></p><p dir="ltr">Talk to your doctor if you think you might have difficulties swallowing the capsules whole (see section 3 &lsquo;How to take Koselugo&rsquo;).&nbsp;</p><p dir="ltr"><strong>Skin, nail and hair problems</strong></p><p dir="ltr">Koselugo can cause skin rash, nail infection or hair thinning or changes in hair color (see section 4 &lsquo;Possible side effects&rsquo;). Tell your doctor if any of these symptoms trouble you during treatment.</p><p dir="ltr"><strong>Children under 3 years old</strong></p><p dir="ltr">Do not give Koselugo to children below 3 years of age. This is because it has not been studied in this age group.</p><p dir="ltr"><strong>Other medicines and Koselugo</strong></p><p dir="ltr">Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes herbal medicines, supplements and medicines obtained without a prescription.</p><p dir="ltr">Koselugo can affect the way some other medicines work. Also, some other medicines can affect the way Koselugo works. Tell your doctor if you are taking any of the following medicines:</p><ul dir="ltr" style="margin-right:40px"><li>clarithromycin or erythromycin (used to treat bacterial infections)</li><li>carbamazepine or phenytoin (used to treat seizures and epilepsy)</li><li>digoxin (used to treat heart failure)</li><li>fexofenadine (used to treat symptoms of allergy)</li><li>fluconazole or itraconazole (used to treat fungal infections)</li><li>ketoconazole (used to treat Cushing&rsquo;s syndrome)</li><li>furosemide (used to treat fluid retention by increasing the amount of urine you pass)</li><li>methotrexate (used to treat some types of cancer, psoriasis or rheumatoid arthritis)</li><li>omeprazole (used to treat acid reflux or stomach ulcer)</li><li>rifampicin (used to treat tuberculosis (TB) and some other bacterial infections)</li><li>St. John&rsquo;s wort (Hypericum perforatum), a herbal medicine (used to treat mild depression and other conditions)</li><li>ticlopidine (used to prevent blood clots)</li></ul><p dir="ltr">Tell your doctor or pharmacist if you are taking or have recently taken any of the above or any other medicines, even those that are not prescribed.</p><p dir="ltr"><strong>Koselugo with food and drink</strong></p><p dir="ltr">Do not drink grapefruit juice while you are taking Koselugo because, it can affect the way the medicine works.</p><p dir="ltr">Pregnancy &ndash; information for women</p><p dir="ltr">Koselugo is not recommended during pregnancy. It may cause harm to an unborn baby.</p><p dir="ltr">If you think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor may ask you to take a pregnancy test before starting treatment.</p><p dir="ltr">You should not become pregnant while taking this medicine. If you are able to become pregnant, you must use effective contraception. See &lsquo;Contraception - information for women and men&rsquo; below.</p><p dir="ltr">If you become pregnant during treatment, tell your doctor straight away.</p><p dir="ltr"><strong>Pregnancy &ndash; information for men</strong></p><p dir="ltr">If your partner becomes pregnant while you are taking this medicine, tell your doctor straight away.</p><p dir="ltr"><strong>Contraception &ndash; information for women and men</strong></p><p dir="ltr">If you are sexually active you should use effective contraception while you are taking this medicine and for at least 1 week after the last dose. It is not known whether Koselugo may interfere with how well hormonal contraceptives work. Please tell your doctor if you are taking a hormonal contraceptive, as your doctor may recommend the addition of a non-hormonal method of birth control.</p><p dir="ltr"><strong>Breast-feeding</strong></p><p dir="ltr">Do not breast-feed if you are taking Koselugo. It is not known if Koselugo passes into breast milk.</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr">Koselugo can cause side effects that affect your ability to drive or use machines. Do not drive or use machines if you feel tired or if you have problems with your vision (such as blurred vision).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>How much to take</strong></p><p dir="ltr">Your doctor will work out the correct dose for you based on your height and weight. The doctor will tell you how many capsules of Koselugo to take.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Your doctor may prescribe a lower dose if you have problems with your liver (hepatic impairment).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Your doctor may reduce your dose if you have certain side effects while you are taking Koselugo (see section&nbsp;4 &lsquo;Possible side effects&rsquo;) or the doctor may interrupt treatment or stop it permanently.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>How to take </strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Koselugo twice a day, about 12&nbsp;hours apart, with or without food.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the capsules whole with water.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not chew, dissolve, or open the capsules.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have, or think you might have difficulty swallowing capsules whole, talk to your doctor before starting treatment.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you are sick</strong></p><p dir="ltr">If you are sick (vomit) at any time after taking Koselugo, do not take an extra dose. Take the next dose at the normal time.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you take more Koselugo than you should</strong></p><p dir="ltr">If you have taken more Koselugo than you should, contact your doctor or pharmacist immediately.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><strong>If you forget to take Koselugo</strong></p><p dir="ltr">What to do if you forget to take a dose of Koselugo depends on how long it is until your next dose.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If it is more than 6&nbsp;hours until your next dose, take the missed dose. Then take the next dose at the normal time.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If it is less than 6&nbsp;hours until your next dose, skip the missed dose. Then take the next dose at</p><p dir="ltr">the normal time.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not take a double dose (two doses at the same time) to make up for a forgotten dose.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>If you stop taking Koselugo</strong></p><p dir="ltr">Do not stop taking Koselugo unless your doctor tells you.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><strong>Possible serious side effects</strong></p><p dir="ltr"><u>Eye (vision) problems </u></p><p dir="ltr">Koselugo can cause eye problems. Tell your doctor straight away if you get blurred vision (a&nbsp;very common side effect that may affect more than 1&nbsp;in&nbsp;10 people) or any other changes to your sight during treatment. Your doctor may ask you to stop taking this medicine or send you to a specialist, if you develop symptoms that include:</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of vision</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dark spots in your vision (floaters)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other changes to your vision (such as reduced vision)</p><p dir="ltr">&nbsp;</p><p dir="ltr">Tell your doctor straight away if you notice any of the serious side effects above.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Other side effects</strong></p><p dir="ltr">Tell your doctor or pharmacist if you notice any of the following side effects:</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Very common (may affect more than 1&nbsp;in&nbsp;10&nbsp;people)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting), feeling sick (nausea)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the mouth (stomatitis)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin and nail problems - signs may include dry skin, rash, redness around the fingernails</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair thinning (alopecia), hair colour change</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired, weak or lacking energy</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (pyrexia)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the hands or feet (peripheral oedema)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a slight decrease in the amount of blood that the heart is pumping (ejection fraction decreased) &ndash; signs may include shortness of breath or swelling in your legs, ankles or feet</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure (hypertension)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced level of albumin, an essential protein in the blood (shown in blood tests)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced haemoglobin, the oxygen-carrying protein in red blood cells (shown in blood tests)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in enzymes (shown in blood tests) suggesting stress on the liver, kidney injury or muscle breakdown</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Common (may affect up to 1&nbsp;in&nbsp;10&nbsp;people)</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;dry mouth</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;swelling of the face (facial oedema)</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;shortness of breath (dyspnoea)</p><p dir="ltr"><strong>&nbsp;</strong></p><p>To report any side effect(s):</p><ul><li><strong><em>Saudi Arabia: </em></strong></li></ul><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>- </strong>The National Pharmacovigilance Centre (NPC)</p><ul><li>Toll free phone: 19999</li><li>E-mail: npc.drug@sfda.gov.sa&nbsp;&nbsp;</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><ul dir="ltr"><li>Other GCC States:</li></ul><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight and reach of children.</p><p dir="ltr">Do not use this medicine after the expiry date which is stated on the bottle and carton after EXP. The expiry date refers to the last day of that month.</p><p dir="ltr">Do not store above 30&deg;C.</p><p dir="ltr">Store in the original bottle in order to protect from moisture and light. Keep the bottle tightly closed.</p><p dir="ltr">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance is Selumetinib. Each Koselugo 10 mg hard capsule contains 10 mg of Selumetinib (as hydrogen sulfate). Each Koselugo 25 mg hard capsule contains 25 mg of Selumetinib (as hydrogen sulfate).</p><p dir="ltr">The other ingredients in Koselugo 10 mg hard capsules are:</p><ul dir="ltr"><li>capsule fill: vitamin E polyethylene glycol succinate (D &alpha;-tocopheryl polyethylene glycol succinate).</li><li>capsule shell: hypromellose (E464), carrageenan (E407), potassium chloride (E508), titanium dioxide (E171), carnauba wax (E903).</li><li>printing ink: shellac standard (E904), iron oxide black (E172), propylene glycol (E1520) ammonium hydroxide (E527).</li></ul><p dir="ltr">The other ingredients in Koselugo 25 mg hard capsules are:</p><ul><li dir="ltr">capsule fill: vitamin E polyethylene glycol succinate (D &alpha;-tocopheryl polyethylene glycol succinate).</li><li dir="ltr">capsule shell: Hypromellose (E464), carrageenan (E407), potassium chloride (E508), titanium dioxide (E171), indigo carmine aluminum lake (E132), iron oxide yellow (E172), carnauba wax (E903), maize starch.</li><li dir="ltr">printing ink: iron oxide red (E172), iron oxide yellow (E172), indigo carmine aluminum lake (E132), carnauba wax (E903), shellac, standard (E904), glyceryl mono-oleate.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Koselugo 10 mg hard capsule is a white to off-white, opaque, hard capsule which has a center band and is marked with “SEL 10” in black ink.
Koselugo 25 mg hard capsule is a blue, opaque, hard capsule which has a center band and is marked with “SEL 25” in black ink.
Koselugo is provided in white plastic bottles, capped with a white (10 mg) or blue (25 mg) child resistant closure containing 60 hard capsules and a silica gel desiccant. Do not remove the desiccant from the bottle and do not swallow it.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Marketing Authorization Holder</strong></p><p dir="ltr">AstraZeneca AB</p><p dir="ltr">SE-151 85 S&ouml;dert&auml;lje</p><p dir="ltr">Sweden</p><p dir="ltr"><strong>Manufacturer</strong></p><p dir="ltr">Patheon Pharmaceuticals Inc.</p><p dir="ltr">2110 East Galbraith Road</p><p dir="ltr">Cincinnati</p><p dir="ltr">Ohio 45237</p><p dir="ltr">United States</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nov 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ما هو كوسيلوجو وكيف يعمل&nbsp;</p><p dir="RTL">يحتوي كوسيلوجو على مادة سيلوميتينيب الفعاّلة.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيلوميتينيب عبارة عن نوع من الأدوية يسمى مثبط MEK. وهو يعمل عن طريق منع بعض البروتينات المشاركة في نمو خلايا الورم.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المتُوقع أن يقلصّ كوسيلوجو الأورام التي تنمو على طول الأعصاب، وتسمى الأورام الليفية العصبية ضفيرية الشكل.&nbsp;</p><p dir="RTL">تحدث هذه الأورام بسبب حالة وراثية تسُمى الورم الليفي العصبي من النوع 1 (NF1).&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">ما هي دواعي استعمال كوسيلوجو&nbsp;</p><p dir="RTL">يسُتخدم كوسيلوجو لعلاج الأطفال الذين تتراوح أعمارهم بين 3 سنوات فما فوق المصابين بالأورام الليفية العصبية ضفيرية الشكل التي لا يمكن إزالتها بالكامل عن طريق الجراحة.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة بشأن كيفية عمل كوسيلوجو أو سبب وصف هذا الدواء لك، فاطرحها على الطبيب المتابع لك.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول كوسيلوجو:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه السيلوميتينيب أو أيّ من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض شديد في الكبد.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ساورتك أيّ شكوك، فتحدثّ إلى الطبيب المتابع لك أو الصيدلي أو الممرضة قبل تناول كوسيلوجو.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحذيرات واحتياطات&nbsp;</p><p dir="RTL">تحدثّ إلى الطبيب المتابع لك، أو الصيدلي أو الممرضة قبل وأثناء العلاج بكوسيلوجو:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في العين&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في القلب&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الكبد&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول مكملات تحتوي على فيتامين هـ&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تتمكن من ابتلاع الكبسولة بالكامل&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبق عليك أيّ مما سبق (أو لم تكن متأكداً)، فتحدثّ إلى الطبيب المتابع لك، أو الصيدلي، أو الممرضة قبل تناول هذا الدواء.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">مشاكل العين&nbsp;</p><p dir="RTL">يمكن أن يسبب كوسيلوجو مشاكل في العين (راجع القسم 4 &quot;الآثار الجانبية المحتملة .)&quot;أخبر الطبيب المتابع لك على الفورإذا أصبت بتشوش الرؤية أو أيةّ تغييرات أخرى في الرؤية أثناء العلاج. يجب أن يفحص الطبيب المتابع لك عينيك إذا كنت تعاني من أيةّ مشاكل جديدة أو متفاقمة في نظرك أثناء تناولك هذا الدواء.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">مشاكل القلب&nbsp;</p><p dir="RTL">يمُكن أن يقُلل كوسيلوجو كمية الدم التي يضخها قلبك (راجع القسم 4 &quot;الآثار الجانبية المحتملة&quot;). سيتحقق الطبيب المتابع لك من مدى كفاءة عمل قلبك قبل وأثناء علاجك بكوسيلوجو.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">مشاكل الكبد&nbsp;</p><p dir="RTL">يمكن أن يزيد كوسيلوجو من كمية بعض إنزيمات الكبد في دمك (راجع القسم 4 &quot;الآثار الجانبية المحتملة&quot;). سيُجري الطبيب المتابع لك اختبارات دم قبل وأثناء العلاج للتحقق من مدى كفاءة عمل كبدك.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">فيتامين هـ التكميلي&nbsp;</p><p dir="RTL">تحتوي كبسولات كوسيلوجو على فيتامين هـ الذي قد يزيد من خطر إصابتك بالنزيف. ويعني هذا أنه يجب عليك إخبار الطبيب المتابع لك إذا كنت تتناول أدوية أخرى تزيد من خطر إصابتك بالنزيف مثل:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض الأسيتيل ساليسيليك (المعروف أيضاً باسم الأسبرين) للألم والالتهاب&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للتخثر (مميعات الدم) مثل الوارفارين أو الأدوية الأخرى المسُتخدمة لمنع جلطات الدم&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكملات الغذائية التي قد تزيد من خطر إصابتك بالنزيف، مثل فيتامين هـ&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">صعوبة بلع الكبسولات&nbsp;</p><p dir="RTL">تحدّث إلى الطبيب المتابع لك إذا كنت تعتقد أنك قد تواجه صعوبات في بلع الكبسولات كاملة (راجع القسم 3 &quot;كيفية تناول كوسيلوجو .)&quot;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">مشاكل في الجلد والأظافر والشعر&nbsp;</p><p dir="RTL">يمكن أن يسبب كوسيلوجو طفح جلدي أو عدوى في الأظافر أو تساقط الشعر أو تغيرات في لون الشعر (راجع القسم 4 &quot;الآثار الجانبية المحتملة&quot;). أخبر الطبيب المتابع لك إذا كان أيّ من هذه الأعراض يزعجك أثناء العلاج.&nbsp;</p><p>&nbsp;</p><p dir="RTL">الأطفال دون 3 أعوام&nbsp;</p><p dir="RTL">لا تعطِ كوسيلوجو للأطفال دون سن 3 سنوات. وذلك لأنه لم يدُرس لدى هذه الفئة العمرية.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأدوية الأخرى وكوسيلوجو&nbsp; أخبر الطبيب المتابع لك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أيةّ أدوية أخرى. ويشمل ذلك الأدوية العشبية والمكملات والأدوية التي تصُرف من دون وصفة طبية.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يؤثر كوسيلوجو على طريقة عمل بعض الأدوية الأخرى. ويمكن أيضاً أن تؤُثر بعض الأدوية الأخرى على طريقة عمل كوسيلوجو. أخبر الطبيب المتابع لك إذا كنت تتناول أيا من الأدوية التالية:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلاريثرومايسين أو إريثروميسين (يسُتخدم لعلاج العدوى البكتيرية)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كربامازيبين أو فينيتوين (يسُتخدم لعلاج التشنجات والصرع)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين (يسُتخدم لعلاج فشل القلب)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيكسوفينادين (يسُتخدم لعلاج أعراض الحساسية)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكونازول أو إيتراكونازول (يسُتخدم لعلاج الالتهابات الفطرية)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول (يسُتخدم لعلاج متلازمة كوشينغ)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فوروسيميد (يسُتخدم لعلاج احتباس السوائل عن طريق زيادة كمية البول التي تخرجها)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتركسيت (يسُتخدم لعلاج بعض أنواع السرطان والصدفية والتهاب المفاصل الروماتويدي)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوميبرازول (يسُتخدم لعلاج ارتجاع المريء أو قرحة المعدة)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (يسُتخدم لعلاج مرض السل (TB) وبعض أنواع العدوى البكتيرية الأخرى)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (العرن المثقوب)، دواء عشبي (يسُتخدم لعلاج الاكتئاب الخفيف والحالات الأخرى)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيكلوبيدين (يسُخدم في منع جلطات الدم).&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرُجى إبلاغ الطبيب المتابع لك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أيا من الأدوية المذكورة أعلاه أو أيةّ أدوية أخرى حتى تلك التي تتناولها بدون وصفة طبية.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">كوسيلوجو مع الطعام والشراب&nbsp;</p><p dir="RTL">لا تشرب عصير الجريب فروت أثناء تناول كوسيلوجو، لأنه قد يؤثر على طريقة عمل الدواء.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحمل - معلومات للنساء&nbsp;</p><p dir="RTL">لا ينُصح باستخدام كوسيلوجو أثناء الحمل. قد يسبب ضرراً للجنين.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ تعتقدين أنكِ حاملاً أو تخططين لإنجاب طفل، فاستشيري الطبيب المتابع لكِ قبل تناول هذا الدواء. قد يطلب منكِ الطبيب المتابع لكِ إجراء اختبار الحمل قبل بدء العلاج.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا تحملي أثناء تناول هذا الدواء. إذا كنتِ قادرة على الحمل، فيجب عليكِ استخدام وسيلة فعالة لمنع الحمل. راجعي &quot;منع الحمل - معلومات للنساء والرجال&quot; أدناه.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبحتِ حاملاً أثناء العلاج، فأخبري الطبيب المتابع لكِ على الفور.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحمل - معلومات للرجال&nbsp;</p><p dir="RTL">إذا أصبحت زوجتك حاملاً أثناء تناولك هذا الدواء، فأخبر الطبيب المتابع لك على الفور.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">منع الحمل - معلومات للنساء والرجال&nbsp;</p><p dir="RTL">إذا كنتِ نشطة جنسياً، فيجب عليكِ استخدام وسيلة فعالة لمنع الحمل أثناء تناول هذا الدواء ولمدة أسبوع واحد على الأقل بعد تناول آخر جرعة. من غير المعروف ما إذا كان كوسيلوجو قد يتداخل مع مدى فعالية وسائل منع الحمل الهرمونية .</p><p dir="RTL">يرُجى إخبار الطبيب المتابع لكِ إذا كنتِ تتناولين أحد وسائل منع الحمل الهرمونية، إذ قد يوُصي الطبيب المتابع لكِ بإضافة طريقة غير هرمونية لتحديد النسل.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الرضاعة الطبيعية&nbsp;</p><p dir="RTL">لا ترضعي طفلكِ طبيعياً إذا كنتِ تتناولين كوسيلوجو. ليس معروفاً ما إذا كان كوسيلوجو ينتقل إلى حليب الثدي.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">القيادة واستخدام الآلات&nbsp;</p><p dir="RTL">يمكن أن يسُبب كوسيلوجو آثاراً جانبية تؤثر على قدرتك على القيادة أو استخدام الآلات. لا تقد السيارة أو تستخدم الآلات إذا كنت تشعر بالتعب أو إذا كنت تعاني من مشكلات في الرؤية (مثل الرؤية المشوشة.)&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائماً على تناول هذا الدواء تماماً كما أخبرك الطبيب المتابع لك أو الصيدلي. استشر الطبيب المتابع لك أو الصيدلي إذا لم تكن متأكداً من طريقة تناوله.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">عدد الأقراص الواجب تناولها&nbsp;</p><p dir="RTL">سيحدد الطبيب المتابع لك الجرعة الصحيحة لك بناءً على طولك ووزنك. سيُخبرك الطبيب بعدد كبسولات كوسيلوجو التي يجب تناولها.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يصف لك طبيبك جرعة أقل إذا كنت تعاني من مشاكل في الكبد (ضعف الكبد.)&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقلل الطبيب المتابع لك جرعتك إذا عانيت من آثار جانبية معينة أثناء تناولك كوسيلوجو (راجع القسم 4 &quot;الآثار الجانبية المحتملة&quot;) أو قد يوقف الطبيب العلاج أو يوقفه نهائياً.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">كيفية التناول&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول كوسيلوجو مرتين يومياً، بفاصل 12 ساعة تقريباً سواء مع الأكل أو بدونه. &nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الكبسولات كاملة مع الماء.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تمضغ الكبسولات أو تذيبها أو تفتحها.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني أو تعتقد أنك قد تواجه صعوبة في بلع الكبسولات كاملة، فتحدث إلى الطبيب المتابع لك قبل بدء العلاج .&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت مريضاً&nbsp;</p><p dir="RTL">إذا كنت مريضاً (تتقيأ) في أيّ وقت بعد تناول كوسيلوجو، فلا تتناول جرعة إضافية. تناول الجرعة التالية في الوقت المحدد.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تناولت كوسيلوجو أكثر مما ينبغي&nbsp;</p><p dir="RTL">إذا تناولت كوسيلوجو أكثر مما ينبغي فتحدثّ إلى الطبيب المتابع لك أو الصيدلي على الفور.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نسيت تناول كوسيلوجو&nbsp;</p><p dir="RTL">يعتمد ما ينبغي عليك فعله في حالة نسيان جرعة من كوسيلوجو على الفترة الزمنية حتى تناول الجرعة التالية.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا بلغت الفترة الزمنية أكثر من 6 ساعات حتى موعد تناول الجرعة التالية، فتناول الجرعة المنسيةّ. ثم تناول الجرعة التالية في الوقت المحدد.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا بلغت الفترة الزمنية أقل من 6 ساعات حتى موعد تناول الجرعة التالية، فتجاوز الجرعة المنسيةّ. ثم تناول الجرعة التالية في&nbsp; الوقت المحدد.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول جرعة مضاعفة (جرعتين في الوقت ذاته) لتعويض الجرعة المنسيةّ.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا توقفت عن تناول كوسيلوجو&nbsp;</p><p dir="RTL">لا تتوقف عن تناول كوسيلوجو إلا إذا أخبرك بذلك الطبيب المتابع لك.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أيةّ أسئلة أخرى حول استخدام هذا الدواء، فاستشر بذلك أو الصيدلي أو الممرضة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسُبب هذا الدواء، شأنه شأن جميع الأدوية، آثاراً جانبية، على الرغم من أنها لا تصيب الجميع.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الخطيرة المحتملة&nbsp; <u>مشاكل في العين (الرؤية)</u>&nbsp; يمكن أن يسبب كوسيلوجو مشاكل في العين. أخبر الطبيب المتابع لك على الفور إذا أصبت بتشوش الرؤية (أحد الآثار الجانبية الشائعة جدا التي قد تؤثر على أكثر من شخص واحد من بين 10 أشخاص) أو أيةّ تغييرات أخرى في الرؤية أثناء العلاج. قد يطلب منك بذلك التوقف عن تناول هذا الدواء أو إرسالك إلى اختصاصي، إذا ظهرت عليك أعراض تشمل:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الألبومين، وهو بروتين الكبد الأساسي في الدم (كما هو موضح في اختبارات الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان البصر&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع داكنة في الرؤية (عوائم)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات أخرى في الرؤية (مثل ضعف الرؤية)&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر الطبيب المتابع لك على الفور إذا لاحظت أيا من الآثار الجانبية الخطيرة المذكورة أعلاه.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية أخرى&nbsp;</p><p dir="RTL">أخبر الطبيب المتابع لك أو الصيدلي إذا لاحظت أيا من الآثار الجانبية التالية:&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة جداً (قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص)&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بالإعياء (التقيؤ) أو الشعور بالإعياء (الغثيان.)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب داخل الفم (التهاب الفم)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الجلد والأظافر - قد تشمل العلامات الجلد الجاف والطفح الجلدي والاحمرار حول الأظافر&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر (داء الثعلبة)، تغير لون الشعر&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب أو الضعف أو نقص الطاقة&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (سخونة)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين أو القدمين (وذمة محيطية)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض طفيف في كمية الدم التي يضخها القلب (انخفاض الكسر القذفي) - قد تشمل العلامات ضيق في التنفس أو تورم في ساقيك أو كاحليك أو قدميك&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم مرتفع (ارتفاع ضغط الدم)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الألبومين، وهو بروتين أساسي للكبد (يظهر في اختبارات الدم)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الهيموجلوبين، وهو البروتين الذي يحمل الأكسجين في خلايا الدم الحمراء (يظهر في اختبارات الدم)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في الإنزيمات (تظهر في اختبارات الدم) مما يشير إلى إجهاد الكبد أو إصابة الكلى أو ضعف العضلات&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة (قد تصيب مايصل إلى شخص واحد من بين 10 أشخاص)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه (وذمة الوجه)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس (عسر التنفس)&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أي أثر (آثار) جانبية او اية مشكلات تتعلق بالجودة:</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكه العربيه السعوديه</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية:</strong></p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الرقم المجاني : </strong><strong>19999</strong></p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>البريد الإلكتروني: </strong><strong>npc.drug@sfda.gov.sa</strong></p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الموقع الإلكتروني: </strong><strong>https://ade.sfda.gov.sa/</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول مجلس التعاون الخليجي الاخرى</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>يرجى الاتصال بالجهة المختصة ذات الصله</strong></p><p dir="LTR">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن متناول الأطفال ورؤيتهم.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء صلاحيته المدونّ على العبوة والعلبة الكرتونية بعد كلمة &rdquo;EXP&ldquo;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في هذا الشهر.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تُخزنّه في درجة حرارة أعلى من 30 درجة مئوية.&nbsp;</p><p dir="RTL">يُخزنّ في العبوة الأصلية لحمايته من الرطوبة والضوء.&nbsp;</p><p dir="RTL">حافظ على العبوة مغلقة بإحكام.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه الإجراءات على حماية البيئة.&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محتويات كوسيلوجو&nbsp; المادة الفعالة هي سيلوميتينيب. تحتوي كل كبسولة صلبة من كوسيلوجو 25 ملغ على 25 ملغ من سيلوميتينيب (كبريتات الهيدروجين). تحتوي كل كبسولة صلبة من كوسيلوجو 25 ملغ على 25 ملغ من سيلوميتينيب (كبريتات الهيدروجين.)&nbsp; المكونات الأخرى في كبسولات كوسيلوجو 10 ملغ الصلبة هي:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعبئة الكبسولة: فيتامين هـ بولي إيثيلين جلايكول سكسينات (د ألفا توكوفيرول بولي إيثيلين جلايكول سكسينات.)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غلاف الكبسولة: هيبروميلوز( E464)، كاراجينان( E407)، كلوريد البوتاسيوم( E508)، ثاني أكسيد التيتانيوم</p><p dir="RTL">(E171)، شمع الكرنوبا( E903).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حبر الطباعة: شيلاك( E904)، أكسيد الحديد الأسود( E172)، بروبيلين غليكول( E1520)، هيدروكسيد الأمونيوم (E527).&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى في كبسولات كوسيلوجو 25 ملغ الصلبة هي:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعبئة الكبسولة: فيتامين هـ بولي إيثيلين جلايكول سكسينات (د ألفا توكوفيرول بولي إيثيلين جلايكول سكسينات.)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غلاف الكبسولة: هيبروميلوز( E464)، كاراجينان( E407)، كلوريد البوتاسيوم( E508)، ثاني أكسيد التيتانيوم</p><p dir="RTL">(E171)، بحيرة الألومنيوم باللون القرمزي النيلي( E132)، أكسيد الحديد الأصفر( E172)، شمع الكرنوبا( E903)، نشا الذرة.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حبر الطباعة: أكسيد الحديد الأحمر( E172)، أكسيد الحديد الأصفر( E172)، بحيرة الألومنيوم باللون القرمزي النيلي( E132)، شمع الكرنوبا( E903)، شيلاك، معيار( E904)، أحادي أوليات الغليسيريل.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">شكل كوسيلوجو ومحتويات العبوة&nbsp;</p><p dir="RTL">كبسولة كوسيلوجو 10 ملغ الصلبة عبارة عن كبسولة صلبة بيضاء إلى بيضاء مصفرة غير شفافة مع خط في المنتصف وتحمل علامة&quot; SEL 10&quot; بالحبر الأسود.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">كبسولة كوسيلوجو الصلبة 25 ملغ عبارة عن كبسولة صلبة زرقاء غير شفافة مع خط في المنتصف وتحمل علامة &quot;25SEL &quot; بالحبر الأسود.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم توفير كوسيلوجو في عبوات بلاستيكية بيضاء، مغطاة بسدادة بيضاء( 10 ملغ) أو زرقاء( 25 ملغ) مقاومة لعبث الأطفال تحتوي على 60 كبسولة صلبة ومجفف جل السيليكا. لا تزُل المادة المجففة من الزجاجة ولا تبتلعها.&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق&nbsp;</strong></p><p dir="RTL">AstraZeneca AB</p><p>SE-151 85 S&ouml;dert&auml;lje&nbsp; &nbsp;</p><p>السويد</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>جهة التصنيع&nbsp;</strong></p><p>Patheon Pharmaceuticals Inc.</p><p>2110 East Galbraith Road</p><p>Cincinnati</p><p>Ohio 45237</p><p>United States</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر 2023 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Koselugo 10 mg hard capsules
Koselugo 25 mg hard capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Koselugo 10 mg hard capsules
Each hard capsule contains 10 mg of Selumetinib (as hydrogen sulfate).

Koselugo 25 mg hard capsules
Each hard capsule contains 25 mg of Selumetinib (as hydrogen sulfate).

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.

Koselugo 10 mg hard capsules
White to off-white, opaque, size 4 (approximately 14 mm x 5 mm), hard capsule, which has a centre band and is marked with “SEL 10” in black ink.

Koselugo 25 mg hard capsules
Blue, opaque, size 4 (approximately 14 mm x 5 mm), hard capsule, which has a centre band and is marked with “SEL 25” in black ink.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>This indication is approved under conditional approval based on tumour response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of long-term safety in post-marketing and confirmatory studies</strong></p><p>&nbsp;</p><p>Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3&nbsp;years and above.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Treatment with Koselugo should be initiated by a physician experienced in the diagnosis and the treatment of patients with NF1 related tumours.</p><p dir="ltr"><u>Posology</u></p><p dir="ltr">The recommended dose of Koselugo is 25&nbsp;mg/m<sup>2</sup> of body surface area (BSA), taken orally twice daily (approximately every 12&nbsp;hours).</p><p dir="ltr">Dosing is individualised based on BSA (mg/m<sup>2</sup>) and rounded to the nearest achievable 5&nbsp;mg or 10&nbsp;mg dose (up to a maximum single dose of 50&nbsp;mg). Different strengths of Koselugo capsules can be combined to attain the desired dose (Table&nbsp;1).</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:607px"><thead><tr><td colspan="2" style="vertical-align:top"><p><strong>Table&nbsp;</strong><!--[if supportFields]><span
   style='mso-bookmark:_Hlk21609188'></span><span style='mso-element:field-begin'></span><span
   style='mso-bookmark:_Hlk21609188'><b><span lang=EN-GB> SEQ Table \* ARABIC <span
   style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>1</strong><!--[if supportFields]><span
   style='mso-bookmark:_Hlk21609188'></span><span style='mso-element:field-end'></span><![endif]--><strong>. Recommended dose based on body surface area</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Body surface area (BSA)<sup> a</sup></strong></p></td><td style="vertical-align:top"><p>Recommended dose</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>0.55 &ndash; 0.69 m<sup>2</sup></p></td><td style="vertical-align:top"><p>20&nbsp;mg in the morning and 10&nbsp;mg in the evening</p></td></tr><tr><td style="vertical-align:top"><p>0.70 &ndash; 0.89 m<sup>2</sup></p></td><td style="vertical-align:top"><p>20&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>0.90 &ndash; 1.09 m<sup>2</sup></p></td><td style="vertical-align:top"><p>25&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>1.10 &ndash; 1.29 m<sup>2</sup></p></td><td style="vertical-align:top"><p>30&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>1.30 &ndash; 1.49 m<sup>2</sup></p></td><td style="vertical-align:top"><p>35&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>1.50 &ndash; 1.69 m<sup>2</sup></p></td><td style="vertical-align:top"><p>40&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>1.70 &ndash; 1.89 m<sup>2</sup></p></td><td style="vertical-align:top"><p>45&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;1.90 m<sup>2</sup></p></td><td style="vertical-align:top"><p>50&nbsp;mg twice daily</p></td></tr></tbody></table><p dir="ltr"><sup>a </sup>the recommended dose for patients with a BSA less than 0.55&nbsp;m<sup>2</sup> has not been established.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Treatment with Koselugo should continue as long as clinical benefit is observed, or until PN progression or the development of unacceptable toxicity. There is limited data in patients older than&nbsp;18, therefore continued treatment into adulthood should be based on benefits and risks to the individual patient as assessed by the physician. However, start of treatment with Koselugo in adults is not appropriate.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Missed dose</u></em></p><p dir="ltr">If a dose of Koselugo is missed, it should only be taken if it is more than 6&nbsp;hours until the next scheduled dose.</p><p dir="ltr"><em><u>Vomiting</u></em></p><p dir="ltr">If vomiting occurs after Koselugo is administered, an additional dose is not to be taken. The patient should continue with the next scheduled dose.</p><p dir="ltr"><em><u>Dose adjustments </u></em></p><p dir="ltr">Interruption and/or dose reduction or permanent discontinuation of Selumetinib may be</p><p dir="ltr">required based on individual safety and tolerability (see sections&nbsp;4.4 and 4.8). Recommended dose reductions are given in Table 2 and may require the daily dose to be divided into two administrations of different strength or for treatment to be given as a once daily dose.</p><p dir="ltr"><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:767px"><thead><tr><td colspan="6" style="vertical-align:top; width:764px"><p><strong>Table&nbsp;</strong><!--[if supportFields]><b><span
   lang=EN-GB><span style='mso-element:field-begin'></span> SEQ Table \* ARABIC
   <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>2</strong><!--[if supportFields]><b><span lang=EN-GB><span
   style='mso-element:field-end'></span></span></b><![endif]--><strong>. Recommended dose reductions for adverse reactions</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Body surface area (BSA)</strong></p></td><td rowspan="2" style="vertical-align:top"><p>Initial Koselugo dose<sup>a</sup></p><p>(mg/twice daily)</p></td><td colspan="2" style="vertical-align:top"><p>First dose reduction (mg/dose)</p></td><td colspan="2" style="vertical-align:top; width:180px"><p>Second dose reduction (mg/dose)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Morning</p></td><td style="vertical-align:top"><p>Evening</p></td><td style="vertical-align:top"><p>Morning</p></td><td style="vertical-align:top; width:76px"><p>Evening</p></td></tr></thead><tbody><tr><td><p>0.55 &ndash; 0.69 m<sup>2</sup></p></td><td><p>20&nbsp;mg in the morning and 10&nbsp;mg in the evening</p></td><td><p>10</p></td><td><p>10</p></td><td colspan="2" style="width:180px"><p>10&nbsp;once daily</p></td></tr><tr><td style="vertical-align:top"><p>0.70 &ndash; 0.89 m<sup>2</sup></p></td><td><p>20</p></td><td><p>20</p></td><td><p>10</p></td><td><p>10</p></td><td style="width:76px"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>0.90 &ndash; 1.09 m<sup>2</sup></p></td><td><p>25</p></td><td><p>25</p></td><td><p>10</p></td><td><p>10</p></td><td style="width:76px"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>1.10 &ndash; 1.29 m<sup>2</sup></p></td><td><p>30</p></td><td><p>25</p></td><td><p>20</p></td><td><p>20</p></td><td style="width:76px"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>1.30 &ndash; 1.49 m<sup>2</sup></p></td><td><p>35</p></td><td><p>25</p></td><td><p>25</p></td><td><p>25</p></td><td style="width:76px"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>1.50 &ndash; 1.69 m<sup>2</sup></p></td><td><p>40</p></td><td><p>30</p></td><td><p>30</p></td><td><p>25</p></td><td style="width:76px"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>1.70 &ndash; 1.89 m<sup>2</sup></p></td><td><p>45</p></td><td><p>35</p></td><td><p>30</p></td><td><p>25</p></td><td style="width:76px"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;1.90 m<sup>2</sup></p></td><td><p>50</p></td><td><p>35</p></td><td><p>35</p></td><td><p>25</p></td><td style="width:76px"><p>25</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup> Based on BSA as shown in Table 1.</p><p dir="ltr"><sup>b </sup>Permanently discontinue treatment in patients unable to tolerate Koselugo after two dose reductions.</p><p dir="ltr">Dose modifications for the management of adverse reactions associated with this medicinal product are presented in Table&nbsp;3<strong>.</strong></p><p dir="ltr"><strong>Table </strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Hlk66117442'><span style='mso-spacerun:yes'> </span>SEQ
Table \* ARABIC <span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>3</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><span style='mso-element:field-end'></span></span></b><![endif]--><strong>. Recommended dose modifications for adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:653px"><tbody><tr><td><p><strong>CTCAE Grade*</strong></p></td><td><p>Recommended dose modification</p></td></tr><tr><td><p><strong>Grade 1 or 2</strong> (tolerable &ndash; can be managed with supportive care)</p></td><td><p>Continue treatment and monitor as clinically indicated</p></td></tr><tr><td><p><strong>Grade 2</strong> (intolerable &ndash; cannot be managed with supportive care) or <strong>Grade 3</strong></p></td><td><p>Interrupt treatment until toxicity is grade 0 or 1 and reduce by one dose level when resuming therapy (see Table&nbsp;2)</p></td></tr><tr><td><p><strong>Grade 4</strong></p></td><td><p>Interrupt treatment until toxicity is grade 0 or 1, reduce by one dose level when resuming therapy (see Table&nbsp;2). Consider discontinuation</p></td></tr></tbody></table><p dir="ltr"><sup>* </sup>Common Terminology Criteria for Adverse Events (CTCAE)</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Dose modification advice for left ventricular ejection fraction (LVEF) reduction</em></p><p dir="ltr">In cases of asymptomatic LVEF reduction of&nbsp; &ge;&nbsp;10 percentage points from baseline and below the institutional lower level of normal (LLN), Selumetinib treatment should be interrupted until resolution. Once resolved, Selumetinib should be reduced by one dose level when resuming therapy (see Table&nbsp;2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In patients who develop symptomatic LVEF reduction or a grade&nbsp;3 or 4 LVEF reduction, Selumetinib should be discontinued, and a prompt cardiology referral should be carried out (see section&nbsp;4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Dose modification advice for ocular toxicities</em></p><p dir="ltr">Selumetinib treatment should be interrupted in patients diagnosed with retinal pigment epithelial detachment (RPED) or central serous retinopathy (CSR) with reduced visual acuity until resolution; reduce Selumetinib by one dose level when resuming therapy (see Table&nbsp;2). In patients diagnosed with RPED or CSR without reduced visual acuity, ophthalmic assessment<strong> </strong>should be conducted every 3&nbsp;weeks until resolution. In patients who are diagnosed with retinal vein occlusion (RVO), treatment with Selumetinib should be permanently discontinued (see section&nbsp;4.4).</p><p dir="ltr"><em>Dose adjustments for co‑administration with CYP3A4 or CYP2C19 inhibitors </em></p><p dir="ltr">Concomitant use of strong or moderate CYP3A4 or CYP2C19 inhibitors is not recommended, and alternative agents should be considered. If a strong or moderate CYP3A4 or CYP2C19 inhibitor must be co-administered, the recommended Koselugo dose reduction is as follows: If a patient is currently taking 25 mg/m<sup>2</sup> twice daily, dose reduce to 20&nbsp;mg/m<sup>2</sup> twice daily. If a patient is currently taking 20&nbsp;mg/m<sup>2 </sup>twice daily, dose reduce to 15&nbsp;mg/m<sup>2</sup> twice daily (see Table&nbsp;4 and section&nbsp;4.5).</p><table border="1" cellspacing="0" cellpadding="0" summary="Recommended Dosage of KOSELUGO for Coadministration with Strong or Moderate CYP3A4 Inhibitors or FluconazoleRecommended Dosage of KOSELUGO for Coadministration with Strong or Moderate CYP3A4 Inhibitors or Fluconazole" dir="ltr" style="width:607px"><thead><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;</strong><!--[if supportFields]><b><span
   lang=EN-GB><span style='mso-element:field-begin'></span> SEQ Table \* ARABIC
   <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>4</strong><!--[if supportFields]><b><span
   lang=EN-GB><span style='mso-element:field-end'></span></span></b><![endif]--><strong>. Recommended dose to achieve 20&nbsp;mg/m<sup>2 </sup>or 15&nbsp;mg/m<sup>2</sup> twice daily dose level</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:bottom"><p>Body Surface Area</p></td><td colspan="2" style="vertical-align:top"><p>20 mg/m<sup>2</sup> twice daily (mg/dose)</p></td><td colspan="2" style="vertical-align:top"><p>15 mg/m<sup>2</sup> twice daily (mg/dose)</p></td></tr><tr><td style="vertical-align:top"><p>Morning</p></td><td style="vertical-align:top"><p>Evening</p></td><td style="vertical-align:top"><p>Morning</p></td><td style="vertical-align:top"><p>Evening</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>0.55 &ndash; 0.69 m<sup>2</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>10</p></td><td colspan="2" style="vertical-align:top"><p>10 mg once a day</p></td></tr><tr><td style="vertical-align:top"><p>0.70 &ndash; 0.89 m<sup>2</sup></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>0.90 &ndash; 1.09 m<sup>2</sup></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>1.10 &ndash; 1.29 m<sup>2</sup></p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>1.30 &ndash; 1.49 m<sup>2</sup></p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>1.50 &ndash; 1.69 m<sup>2</sup></p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>25</p></td></tr><tr><td style="vertical-align:top"><p>1.70 &ndash; 1.89 m<sup>2</sup></p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>25</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 1.90 m<sup>2</sup></p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>30</p></td></tr></tbody></table><p dir="ltr"><u>Special populations</u></p><p dir="ltr"><em><u>Renal impairment</u></em></p><p dir="ltr">Based on clinical trials no dose adjustment is recommended in patients with mild, moderate, severe renal impairment or those with end stage renal disease (ESRD) (see section&nbsp;5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Hepatic impairment</u></em></p><p dir="ltr">Based on clinical trials, no dose adjustment is recommended in patients with mild hepatic impairment. The starting dose should be reduced in patients with moderate hepatic impairment to 20&nbsp;mg/m<sup>2</sup> BSA, twice daily (see Table&nbsp;4). Koselugo is contraindicated for use in patients with severe hepatic impairment (see sections&nbsp;4.3&nbsp;and 5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Ethnicity</u></em></p><p dir="ltr">Increased systemic exposure has been seen in adult Asian subjects, although there is considerable overlap with Western subjects when corrected for body weight. No specific adjustment to the starting dose is recommended for paediatric Asian patients, however these patients, should be closely monitored for adverse events (see section&nbsp;5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Paediatric population</u></em></p><p dir="ltr">The safety and efficacy of Koselugo in children less than 3&nbsp;years of age has not been established. No data are available.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr">Koselugo is for oral use. It can be taken with or without food (see section&nbsp;5.2).</p><p dir="ltr">The capsules should be swallowed whole with water. The capsules should not be chewed, dissolved, or opened, because this could impair drug release and affect the absorption of Selumetinib&nbsp;&nbsp;</p><p dir="ltr">Koselugo should not be administered to patients who are unable or unwilling to swallow the capsule whole. Patients should be assessed for their ability to swallow a capsule before starting treatment. &nbsp;Standard medicine swallowing techniques are expected to be sufficient to swallow Selumetinib capsules. For patients who have difficulties swallowing the capsule, referral to an appropriate health care professional such as a speech and language therapist could be considered to identify suitable methods that can be tailored to the particular patient.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Severe hepatic impairment (see sections 4.2 and 5.2).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Left ventricular ejection fraction (LVEF) reduction</u></p><p>Asymptomatic decreases in ejection fraction have been reported in 22% of paediatric patients in the pivotal clinical trial. Median time to initial onset of these adverse reactions was 226&nbsp;days. A small number of serious reports of LVEF reduction associated with Selumetinib have been reported in paediatric patients who participated in an expanded access program (see section 4.8).</p><p>&nbsp;</p><p>Paediatric patients with a history of impaired left ventricular function or a baseline LVEF below institutional LLN have not been studied. LVEF should be evaluated by echocardiogram before initiation of treatment to establish baseline values. Prior to starting Selumetinib treatment, patients should have an ejection fraction above the institutional LLN.</p><p>&nbsp;</p><p>LVEF should be evaluated at approximately 3‑month intervals, or more frequently as clinically indicated, during treatment. Reduction in LVEF can be managed using treatment interruption, dose reduction or treatment discontinuation (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Ocular toxicity</u></p><p>Patients should be advised to report any new visual disturbances. Adverse reactions of blurred vision have been reported in paediatric patients receiving Selumetinib. Isolated cases of RPED, CSR and RVO in adult patients with multiple tumour types, receiving treatment with Selumetinib monotherapy and in combination with other anti-cancer agents, and in a single paediatric patient with pilocytic astrocytoma on Selumetinib monotherapy, have been observed (see section&nbsp;4.8).</p><p>&nbsp;</p><p>In line with clinical practice an ophthalmological evaluation prior to treatment initiation and at any time a patient reports new visual disturbances is recommended. In patients diagnosed with RPED or CSR without reduced visual acuity, ophthalmic assessment should be conducted every 3&nbsp;weeks until resolution. If RPED or CSR is diagnosed and visual acuity is affected, Selumetinib therapy should be interrupted, and the dose reduced when treatment is resumed (see section&nbsp;4.2). If RVO is diagnosed, treatment with Selumetinib should be permanently discontinued (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Liver laboratory abnormalities </u></p><p>Liver laboratory abnormalities, specifically AST and ALT elevations, can occur with Selumetinib (see section&nbsp;4.8). Liver laboratory values should be monitored before initiation of Selumetinib and at least monthly during the&nbsp;6&nbsp;first months of treatment, and thereafter as clinically indicated. Liver laboratory abnormalities should be managed with dose interruption, reduction or treatment discontinuation (see Table&nbsp;2 in section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Skin and subcutaneous disorders </u></p><p>Skin rash (including maculopapular rash and acneiform rash), paronychia and hair changes have been reported very commonly in the pivotal clinical study (see section 4.8). Pustular rash, hair color</p><p>changes and dry skin were seen more frequently in younger children (age 3-11 years) and acneiform rash was seen more frequently in post-pubertal children (age 12-16 years).</p><p>&nbsp;</p><p><u>Vitamin E supplementation</u></p><p>Patients should be advised not to take any supplemental vitamin E. Koselugo 10&nbsp;mg capsules contain 32&nbsp;mg vitamin E as the excipient, D-alpha-tocopheryl polyethylene glycol 1000&nbsp;succinate (TPGS). Koselugo 25&nbsp;mg capsules contain 36&nbsp;mg vitamin E as TPGS. High doses of vitamin E may increase the risk of bleeding in patients taking concomitant anticoagulant or antiplatelet medicinal products (e.g., warfarin or acetylsalicylic acid). Anticoagulant assessments, including international normalised ratio or prothrombin time, should be conducted more frequently to detect when dose adjustments of the anticoagulant or antiplatelet medicinal products are warranted (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Risk of choking</u></p><p>Selumetinib is available as a capsule which must be swallowed whole. Some patients, in particular children &lt; 6 years of age, may be at risk of choking on a capsule formulation due to developmental, anatomical or psychological reasons. Therefore, Selumetinib should not be administered to patients who are unable or unwilling to swallow the capsule whole (see section 4.2).</p><p>&nbsp;</p><p><u>Women of childbearing potential</u></p><p>Koselugo is not recommended in women of childbearing potential who are not using contraception (see section 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Interaction studies have only been performed in healthy adults (aged &ge;&nbsp;18&nbsp;years).</p><p dir="ltr"><em><u>&nbsp;</u></em></p><p dir="ltr"><em><u>Active substances that may increase selumetinib plasma concentrations</u></em></p><p dir="ltr">Co-administration with a strong CYP3A4 inhibitor (200&nbsp;mg itraconazole twice daily for 4&nbsp;days) increased selumetinib C<sub>max</sub> by 19% (90%&nbsp;CI 4, 35) and AUC by 49% (90%&nbsp;CI 40, 59) in healthy adult subjects.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Co-administration with a strong CYP2C19/moderate CYP3A4 inhibitor (200&nbsp;mg fluconazole once daily for 4&nbsp;days) increased selumetinib C<sub>max</sub> by 26% (90%&nbsp;CI 10, 43) and AUC by 53% (90%&nbsp;CI 44, 63) in healthy adult subjects, respectively.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Concomitant use of erythromycin (moderate CYP3A4 inhibitor) or fluoxetine (strong CYP2C19/CYP2D6 inhibitor) is predicted to increase selumetinib AUC by ~30-40% and C<sub>max</sub> by ~20%.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Co-administration with strong inhibitors of CYP3A4 (e.g., clarithromycin, grapefruit juice, oral ketoconazole) or&nbsp;CYP2C19 (e.g., ticlopidine) should be avoided. Co‑administration with moderate inhibitors of CYP3A4 (e.g., erythromycin and fluconazole) and CYP2C19 (e.g., omeprazole) should be avoided.</p><p dir="ltr">If co‑administration is unavoidable, patients should be carefully monitored for adverse events and the selumetinib dose should be reduced (see section&nbsp;4.2 and Table&nbsp;4).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Active substances that may decrease selumetinib plasma concentrations</u></em></p><p dir="ltr">Co-administration with a strong CYP3A4 inducer (600&nbsp;mg rifampicin daily for 8&nbsp;days) decreased selumetinib C<sub>max</sub> by -26% (90%&nbsp;CI ‑17, ‑34) and AUC by -51% (90%&nbsp;CI ‑47, ‑54).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Concomitant use of strong CYP3A4 inducers (e.g., phenytoin, rifampicin, carbamazepine, St.&nbsp;John&rsquo;s Wort) or moderate CYP3A4 inducers with Koselugo should be avoided.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Active substances whose plasma concentrations may be altered by selumetinib</u></em></p><p dir="ltr"><em>In vitro, </em>selumetinib is an inhibitor of OAT3. The potential for a clinically relevant effect on the pharmacokinetics of concomitantly administered substrates of OAT3 (e.g., methotrexate and furosemide) cannot be excluded (see section&nbsp;5.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">TPGS is a P-gp inhibitor <em>in vitro</em> and it cannot be excluded that it may cause clinically relevant drug interactions with substrates of P-gp (e.g., digoxin or fexofenadine).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The effect of selumetinib on the exposure of oral contraceptives has not been evaluated. Therefore, use of an additional barrier method should be recommended to women using hormonal contraceptives (see section 4.6).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Effect of gastric acid reducing agents on selumetinib</u></em></p><p dir="ltr">Selumetinib capsules do not exhibit pH dependent dissolution. Koselugo can be used concomitantly with gastric pH modifying agents (i.e., H2‑receptor antagonists and proton pump inhibitors) without restrictions, except for omeprazole which is a CYP2C19 inhibitor.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Vitamin E</u></em></p><p dir="ltr">Koselugo capsules contain vitamin E as the excipient TPGS. Therefore, patients should avoid taking supplemental vitamin&nbsp;E and anticoagulant assessments should be performed more frequently in patients taking concomitant anticoagulant or antiplatelet medicinal products (see section&nbsp;4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in males and females</u></p><p>Women of childbearing potential should be advised to avoid becoming pregnant while receiving Koselugo. It is recommended that a pregnancy test should be performed on women of childbearing potential prior to initiating treatment.</p><p>&nbsp;</p><p>Both male and female patients (of reproductive potential) should be advised to use effective contraception during and for at least 1&nbsp;week after completion of treatment with Koselugo. It cannot be excluded that Selumetinib may reduce the effectiveness of oral contraceptives, therefore women using hormonal contraceptives should be recommended to add a barrier method (see section 4.5).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are no data on the use of Selumetinib in pregnant women. Studies in animals have shown reproductive toxicity including embryofoetal death, structural defects and reduced foetal weights (see section&nbsp;5.3). Koselugo is not recommended during pregnancy and in women of childbearing potential not using contraception (see section&nbsp;4.4).</p><p>&nbsp;</p><p>If a female patient or a female partner of a male patient receiving Koselugo becomes pregnant, she should be apprised of the potential risk to the foetus.</p><p><strong>&nbsp;</strong></p><p><u>Breast-feeding</u></p><p>It is not known whether Selumetinib, or its metabolites, are excreted in human milk. Selumetinib and its active metabolite are excreted in the milk of lactating mice (see section&nbsp;5.3). A risk to the breast-fed child cannot be excluded, therefore breast-feeding should be discontinued during treatment with Koselugo.</p><p><strong>&nbsp;</strong></p><p><u>Fertility</u></p><p>There are no data on the effect of Koselugo on human fertility. Selumetinib had no impact on fertility and mating performance in male and female mice, although a reduction in embryonic survival was observed in female mice (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Koselugo may have a minor influence on the ability to drive and use machines. Fatigue, asthenia and visual disturbances have been reported during treatment with Selumetinib and patients who experience these symptoms should observe caution when driving or using machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Summary of the safety profile</u></p><p dir="ltr">The safety profile of selumetinib monotherapy in paediatric patients with NF1 who have inoperable PN has been determined following evaluation of a combined safety population of 74&nbsp;paediatric patients (20-30&nbsp;mg/m<sup>2</sup> twice daily). This paediatric &lsquo;pool&rsquo; of patients comprised 50&nbsp;patients in SPRINT Phase II Stratum 1, treated with selumetinib 25&nbsp;mg/m<sup>2 </sup>twice daily (the pivotal dataset) and 24&nbsp;patients in SPRINT Phase I treated with 20&nbsp;to 30&nbsp;mg/m<sup>2</sup> selumetinib twice daily (the dose finding study). There were no clinically relevant differences in the safety profile between SPRINT Phase I and SPRINT Phase II Stratum 1. This safety profile was also substantiated by a pool of safety data from 7&nbsp;AstraZeneca sponsored studies in&nbsp;adult patients with multiple tumour types (N&nbsp;=&nbsp;347) who received 75&nbsp;to&nbsp;100&nbsp;mg twice daily).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the paediatric pool, the median total duration of selumetinib treatment in paediatric patients with NF1 who have PN was 55&nbsp;months (range: &lt;&nbsp;1&nbsp;to 97&nbsp;months), 61% of patients were exposed to selumetinib treatment for &gt;&nbsp;48&nbsp;months and 16% for &gt;72 months. Patients aged &ge;&nbsp;2 to&nbsp;11 years (N&nbsp;=&nbsp;45) had a higher incidence of the following adverse drug reactions (ADRs) compared to patients aged 12 to 18&nbsp;years (N&nbsp;=&nbsp;29):&nbsp;hypoalbuminaemia, dry skin, pyrexia, hair colour changes, rash maculo-papular and paronychia.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the paediatric pool (N&nbsp;=&nbsp;74; comprising 50 patients from the pivotal SPRINT Phase II Stratum&nbsp;1&nbsp;dataset and 24&nbsp;patients from the supportive SPRINT Phase I dataset), the most common adverse reactions of any grade (incidence &ge;&nbsp;45%) were vomiting (86%), diarrhoea (81%), blood creatine phosphokinase increased (77%), nausea (77%), dry skin (65%), pyrexia (61%), dermatitis acneiform (61%), asthenic events (59%), paronychia (57%), stomatitis (55%), haemoglobin decreased (54%), non-acneiform rashes (53%), hypoalbuminaemia (51%), and aspartate aminotransferase increased (51%). Dose interruptions and reductions due to adverse events were reported in 82% and 39% of patients, respectively. The most commonly reported ADRs leading to dose modification (dose interrupted or dose reduced) of selumetinib were vomiting (32%), paronychia (23%), nausea (19%), diarrhoea (15%) and pyrexia (11%). Permanent discontinuation due to adverse events was reported in 12% of the patients. The following serious adverse reactions were reported: diarrhoea (3%), anaemia&nbsp;(3%), pyrexia (3%), blood CPK increased (3%), blood creatinine increased (1%), oedema peripheral (1%) and vomiting (1%).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Tabulated list of adverse reactions</u></p><p dir="ltr">Table&nbsp;5 presents the adverse reactions identified in the paediatric population with NF1 who have inoperable PN and in adult patients (see footnote to Table&nbsp;5). The frequency is determined from the paediatric pool (N&nbsp;=&nbsp;74); comprising 50 patients from the pivotal SPRINT Phase II Stratum 1&nbsp;dataset and 24&nbsp;patients from the supportive SPRINT Phase I dataset. Adverse drug reactions (ADRs) are organised by MedDRA system organ class (SOC). Within each SOC, preferred terms are arranged by decreasing frequency and then by decreasing seriousness. Frequencies of occurrence of adverse reactions are defined as: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000) and not known (cannot be estimated from available data), including isolated reports.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Table&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk25850900'><span style='mso-bookmark:_Hlk16602838'><span
style='mso-bookmark:_Hlk70028553'></span></span></span><span style='mso-element:
field-begin'></span><span style='mso-bookmark:_Hlk25850900'><span
style='mso-bookmark:_Hlk16602838'><span style='mso-bookmark:_Hlk70028553'><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'> SEQ Table \* ARABIC <span style='mso-element:field-separator'></span></span></b></span></span></span><![endif]--><strong>5</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk25850900'><span style='mso-bookmark:_Hlk16602838'><span
style='mso-bookmark:_Hlk70028553'></span></span></span><span style='mso-element:
field-end'></span><![endif]--><strong>. Adverse drug reactions reported in &nbsp;the paediatric pool (pivotal SPRINT Phase II Stratum 1 [N&nbsp;=&nbsp;50] and supportive SPRINT Phase I [N&nbsp;=&nbsp;24]) and in other identified clinical trials in adult patients (N = 347)</strong><sup>&dagger;&dagger;</sup></p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:596px"><thead><tr><td style="vertical-align:top"><p><strong>MedDRA SOC</strong></p></td><td style="vertical-align:top"><p><strong>MedDRA Term</strong></p></td><td style="vertical-align:top"><p><strong>Overall Frequency</strong></p><p><strong>(All CTCAE grades)</strong></p><p><strong>&nbsp;</strong></p><p><strong>NF1 paediatric pool</strong><sup>&Dagger;</sup></p><p><strong>(N&nbsp;= 74)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Frequency of CTCAE grade 3 and Above<sup>&dagger;</sup></strong></p><p><strong>&nbsp;</strong></p><p><strong>NF1 paediatric pool</strong><sup>&Dagger;</sup><strong> </strong></p><p><strong>(N&nbsp;= 74)</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td rowspan="3" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Vision blurred<sup>^</sup></p></td><td style="vertical-align:top"><p>Very common (15%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Retinal pigment epithelial detachment (RPED)/ Central serous retinopathy (CSR)* &dagger;&dagger;</p></td><td style="vertical-align:top"><p>Uncommon (0.6%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Retinal vein occlusion (RVO)* &dagger;&dagger;</p></td><td style="vertical-align:top"><p>Uncommon (0.3%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic &amp; mediastinal disorders</p></td><td style="vertical-align:top"><p>Dyspnoea*</p></td><td style="vertical-align:top"><p>Common (8%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Vomiting<sup>^</sup></p></td><td style="vertical-align:top"><p>Very common (86%)</p></td><td style="vertical-align:top"><p>Common (9%)</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea<sup>^</sup></p></td><td style="vertical-align:top"><p>Very common (81%)</p></td><td style="vertical-align:top"><p>Very common (15%)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea<sup>^</sup></p></td><td style="vertical-align:top"><p>Very common (77%)</p></td><td style="vertical-align:top"><p>Common (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis<sup>^</sup></p></td><td style="vertical-align:top"><p>Very common (55%)</p></td><td style="vertical-align:top"><p>Common (1%)</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>Common (5%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Dry skin</p></td><td style="vertical-align:top"><p>Very common (65%)</p></td><td style="vertical-align:top"><p>Common (1%)</p></td></tr><tr><td style="vertical-align:top"><p>Dermatitis acneiform<sup>^</sup></p></td><td style="vertical-align:top"><p>Very common (61%)</p></td><td style="vertical-align:top"><p>Common (4%)</p></td></tr><tr><td style="vertical-align:top"><p>Paronychia<sup>^</sup></p></td><td style="vertical-align:top"><p>Very common (57%)</p></td><td style="vertical-align:top"><p>Very common (14%)</p></td></tr><tr><td style="vertical-align:top"><p>Rashes (non-acneiform)<sup> ^</sup> *</p></td><td style="vertical-align:top"><p>Very common (53%)</p></td><td style="vertical-align:top"><p>Common (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Hair changes<sup>^</sup> *</p></td><td style="vertical-align:top"><p>Very common (39%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>General disorders</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Very common (61%)</p></td><td style="vertical-align:top"><p>Common (8%)</p></td></tr><tr><td style="vertical-align:top"><p>Asthenic events*</p></td><td style="vertical-align:top"><p>Very common (59%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral oedema*</p></td><td style="vertical-align:top"><p>Very common (31%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Facial oedema*</p></td><td style="vertical-align:top"><p>Common (8%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Investigations</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood CPK increased<sup>^</sup></p></td><td style="vertical-align:top"><p>Very common (77%)</p></td><td style="vertical-align:top"><p>Common (9%)</p></td></tr><tr><td style="vertical-align:top"><p>Haemoglobin decreased*</p></td><td style="vertical-align:top"><p>Very common (54%)</p></td><td style="vertical-align:top"><p>Common (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypoalbuminaemia</p></td><td style="vertical-align:top"><p>Very common (51%)</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>AST increased</p></td><td style="vertical-align:top"><p>Very common (51%)</p></td><td style="vertical-align:top"><p>Common (1%)</p></td></tr><tr><td style="vertical-align:top"><p>ALT increased</p></td><td style="vertical-align:top"><p>Very common (39%)</p></td><td style="vertical-align:top"><p>Common (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Very common (32%)</p></td><td style="vertical-align:top"><p>Common (1%)</p></td></tr><tr><td style="vertical-align:top"><p>Ejection fraction decreased<sup>^</sup></p></td><td style="vertical-align:top"><p>Very common (28%)</p></td><td style="vertical-align:top"><p>Common (1%)</p></td></tr><tr><td style="vertical-align:top"><p>Increased blood pressure*</p></td><td style="vertical-align:top"><p>Very common (18%)</p></td><td style="vertical-align:top"><p>-</p></td></tr></tbody></table><p dir="ltr">Per National Cancer Institute CTCAE version 4.03</p><p dir="ltr">CPK = creatine phosphokinase; AST = aspartate aminotransferase; ALT = alanine aminotransferase</p><p dir="ltr"><sup>^</sup> See Description of selected adverse reactions</p><p dir="ltr"><sup>&dagger;</sup> All reactions were CTCAE grade 3, except for one CTCAE grade 4 event of blood CPK increased and one CTCAE grade 4 event of blood creatinine increased. There were no deaths.</p><p dir="ltr"><sup>&dagger;&dagger; </sup>Identified ADRs from other clinical trial experience in adult patients (N = 347), with multiple tumour types, receiving treatment with selumetinib (75 mg twice daily). These ADRs have not been reported in paediatric population with NF1 who have inoperable PN.</p><p dir="ltr"><sup>&Dagger;</sup><sup> </sup>Paediatric pool (N = 74) percentage rounded to the nearest decimal.</p><p dir="ltr">*ADRs based on grouping of individual preferred terms (PT):</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthenic events: asthenia, fatigue</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CSR/RPED: Detachment of macular retinal pigment epithelium, chorioretinopathy<sup> </sup></p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnoea: dyspnoea exertional, dyspnoea, dyspnoea at rest</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Facial oedema: face odema, periorbital oedema</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haemoglobin decreased: anaemia, haemoglobin decreased</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair changes: alopecia, hair colour change</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood pressure: blood pressure increased, hypertension</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peripheral oedema: oedema peripheral, oedema, localised oedema, peripheral swelling</p><p dir="ltr">Rashes (non-acneiform): rash pruritic, rash maculo-papular, rash papular, rash, rash erythematous, rash macular</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RVO: retinal vascular disorder, retinal vein occlusion, retinal vein thrombosis</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="ltr"><u>Description of selected adverse reactions</u></p><p dir="ltr"><em><u>&nbsp;</u></em></p><p dir="ltr"><em><u>Left ventricular ejection fraction (LVEF) reduction </u></em></p><p dir="ltr">In SPRINT, Phase II Stratum 1, LVEF reduction (PT: ejection fraction decreased) was reported in 13&nbsp;(26%) patients; all cases were grade&nbsp;2, asymptomatic and did not lead to discontinuation; one&nbsp;(2%)&nbsp;case led to dose interruption then reduction. Of the 13&nbsp;patients, 11&nbsp;patients recovered and for 2&nbsp;patients the outcome was not reported. The median time to first occurrence of LVEF reduction was 232&nbsp;days (median duration 252&nbsp;days). The majority of LVEF reduction adverse reactions were reported as reductions from baseline (&ge;&nbsp;10% reduction) but were considered to remain in the normal range. Patients with LVEF lower than the institutional LLN at baseline were not included in the pivotal study. In addition, a small number of serious cases of LVEF reduction associated with selumetinib have been reported in paediatric patients who participated in an expanded access program. For clinical management of LVEF reduction (see sections 4.2 and 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Ocular toxicity</u></em></p><p dir="ltr">In SPRINT, Phase II Stratum 1, grade&nbsp;1 and 2 adverse reactions of blurred vision were reported in 7&nbsp;(14%) patients. Two patients required dose interruption. All adverse reactions were managed without dose reduction. For clinical management of new visual disturbances (see sections 4.2 and 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In addition, a single event of RPED was reported in a paediatric patient receiving selumetinib monotherapy (25&nbsp;mg/m<sup>2</sup> twice daily) for pilocytic astrocytoma involving the optic pathway in an externally sponsored paediatric study (see sections&nbsp;4.2 and&nbsp;4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Paronychia</u></em></p><p dir="ltr">In SPRINT, Phase II Stratum 1, paronychia was reported in 28&nbsp;(56%) patients, the median time to first onset of maximum grade paronychia adverse reaction was&nbsp;423 days and the median duration of adverse reactions was 51&nbsp;days. The majority of these adverse reactions were grade&nbsp;1 or 2 and were treated with supportive or symptomatic therapy and/or dose modification. Grade &ge;&nbsp;3 events occurred in 4 (8%) patients. Ten patients (3&nbsp;with a maximum grade 3 adverse reaction and 7 with a maximum grade 2 adverse reaction) had a selumetinib dose interruption for adverse reactions of paronychia, of whom 5 had dose interruption followed by dose reduction (2&nbsp;patients required a second dose reduction). In one patient (2%) the event led to discontinuation.</p><p dir="ltr"><em><u>&nbsp;</u></em></p><p dir="ltr"><em><u>Blood creatine phosphokinase (CPK) increase </u></em></p><p dir="ltr">Adverse reactions of blood CPK elevation occurred in 39 (78%) of patients in SPRINT Phase II Stratum 1. The median time to first onset of the maximum grade CPK increase was 112&nbsp;days and the median duration of adverse reactions was 153&nbsp;days. The majority of adverse reactions were grade&nbsp;1 or 2 and resolved with no change in selumetinib dose.<sup> </sup>Grade &ge;&nbsp;3 adverse reactions occurred in 3&nbsp;(6%)&nbsp;patients. A grade&nbsp;4 adverse reaction led to treatment interruption followed by dose reduction.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>Gastrointestinal toxicities</u></em></p><p dir="ltr">In SPRINT, Phase II Stratum 1, vomiting (43&nbsp;patients, 86%, median duration 3&nbsp;days), diarrhoea (37&nbsp;patients, 74%, median duration 6&nbsp;days), nausea (36&nbsp;patients, 72%, median duration 15&nbsp;days), and stomatitis (26&nbsp;patients, 52%, median duration 27 days) were the most commonly reported gastrointestinal (GI) reactions. The majority of these cases were grade&nbsp;1 or 2 and did not require any dose interruptionsor dose reductions.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Grade 3 adverse reactions were reported for diarrhoea (8&nbsp;patients, 16%), nausea (2&nbsp;patients, 4%), and vomiting (4&nbsp;patients, 8%). For one patient diarrhoea led to dose reduction and subsequent discontinuation. No dose reduction or discontinuation was required for adverse reactions of nausea, vomiting or stomatitis.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Skin toxicities</u></em></p><p dir="ltr">In SPRINT, Phase II Stratum 1, dermatitis acneiform was observed in 28&nbsp;(56%) patients (median time to onset 43&nbsp;days; median duration of&nbsp;202 days for the maximum CTCAE grade event). The majority of these cases were grade&nbsp;1 or 2, observed in post-pubertal patients (&gt;&nbsp;12&nbsp;years) and did not require any dose interruptions or reductions. Grade 3 adverse reactions were reported in 3 (6%) patients.</p><p dir="ltr"><sup>&nbsp;</sup></p><p dir="ltr">Other (non-acneiform) rashes were observed in 27 (54%) patients in the pivotal study and were predominantly grade&nbsp;1 or 2.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Hair changes</u></em></p><p dir="ltr">In SPRINT, Phase II Stratum 1, 16 (32%) of patients experienced hair changes (reported as hair lightening [PT: hair colour changes] in 12 patients (24%) and hair thinning [PT: alopecia] in&nbsp;12&nbsp;patients (24%)); in 8&nbsp;patients (16%) both alopecia and hair colour changes were reported during treatment. All cases were grade&nbsp;1 and did not require dose interruption or dose reduction.</p><p dir="ltr">&nbsp;</p><p dir="ltr">To report any side effect(s):</p><ul dir="ltr"><li><strong><em>Saudi Arabia: </em></strong></li></ul><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>- The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp;&nbsp; Toll free phone: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa &nbsp;&nbsp;</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp; Other GCC States:</p><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">There is no specific treatment for overdose. If overdose occurs, patients should be closely monitored for signs and symptoms of adverse reactions and treated supportively with appropriate monitoring as necessary. Dialysis is ineffective in the treatment of overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitor, ATC code<em>: </em>L01EE04</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr">Selumetinib is a selective inhibitor of mitogen activated protein kinase kinases 1 and 2 (MEK 1/2). Selumetinib blocks MEK activity and the RAF-MEK-ERK pathway. Therefore, MEK inhibition can block the proliferation and survival of tumour cells in which the RAF-MEK-ERK pathway is activated.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Clinical efficacy</u></p><p dir="ltr">The efficacy of Koselugo was evaluated in an open-label, multi-centre, single-arm study (SPRINT) Phase&nbsp;II Stratum 1 of 50&nbsp;paediatric patients with NF1 inoperable PN that caused significant morbidity. Inoperable PN was defined as a PN that could not be surgically completely removed without risk for substantial morbidity due to encasement of, or close proximity to, vital structures, invasiveness, or high vascularity of the PN. Patients were excluded for the following ocular toxicities: any current or past history of CSR, current or past history of RVO, known intraocular pressure &gt;&nbsp;21&nbsp;mmHg (or upper limit of normal adjusted by age) or uncontrolled glaucoma. Patients received 25&nbsp;mg/m<sup>2</sup> (BSA) twice daily, for 28&nbsp;days (1&nbsp;treatment cycle), on a continuous dosing schedule. Treatment was discontinued if a patient was no longer deriving clinical benefit, experienced unacceptable toxicity or PN progression, or at the discretion of the investigator.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The target PN, the PN that caused relevant clinical symptoms or complications (PN-related morbidities), was evaluated for response rate using centrally read volumetric&nbsp;magnetic resonance imaging (MRI) analysis per Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) criteria. Tumour response was evaluated at baseline and while on treatment after every 4&nbsp;cycles for 2&nbsp;years, and then every 6&nbsp;cycles.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients had target PN MRI volumetric evaluations and clinical outcome assessments, which included functional assessments and patient reported outcomes.</p><p dir="ltr">&nbsp;</p><p dir="ltr">At enrolment, the median age of the patients was 10.2&nbsp;years (range: 3.5&nbsp;to&nbsp;17.4&nbsp;years), 60% were male and 84% were Caucasian.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median target PN volume at baseline was 487.5 mL (range: 5.6 - 3820 mL). PN-related morbidities that were present in &ge;&nbsp;20% of patients included disfigurement, motor dysfunction, pain, airway dysfunction, visual impairment, and bladder/bowel dysfunction.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The primary efficacy endpoint was objective response rate (ORR), defined as the percentage of patients with complete response (defined as disappearance of the target PN) or confirmed partial response (defined as &ge;&nbsp;20% reduction in PN volume, confirmed at a subsequent tumour assessment within 3‑6&nbsp;months), based on National Cancer Institute (NCI) centralised review. Duration of response (DoR) was also evaluated.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Efficacy results are provided based on a data cut-off of March 2021, unless stated otherwise.</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:606px"><thead><tr><td colspan="2" style="vertical-align:top"><p><strong>Table&nbsp;</strong><!--[if supportFields]><span
   style='mso-bookmark:_Hlk527547287'><span style='mso-bookmark:_Hlk21601036'></span></span><span
   style='mso-element:field-begin'></span><span style='mso-bookmark:_Hlk527547287'><span
   style='mso-bookmark:_Hlk21601036'><b style='mso-bidi-font-weight:normal'><span
   lang=EN-GB style='mso-bidi-font-size:11.0pt'> SEQ Table \* ARABIC <span
   style='mso-element:field-separator'></span></span></b></span></span><![endif]--><strong>6</strong><!--[if supportFields]><span
   style='mso-bookmark:_Hlk527547287'><span style='mso-bookmark:_Hlk21601036'></span></span><span
   style='mso-element:field-end'></span><![endif]--><strong>. Efficacy results from SPRINT<sup> </sup>Phase II Stratum 1</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Efficacy parameter </strong></p></td><td style="vertical-align:top"><p><strong>SPRINT</strong></p><p><strong>(N&nbsp;=&nbsp;50)</strong></p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Objective response rate<sup> a, b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Objective response rate, % (95% CI)</p></td><td style="vertical-align:top"><p>34 (68%) (53.3 - 80.5)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Confirmed partial response, n (%)<sup>b</sup></p></td><td style="vertical-align:top"><p>34(68%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Duration of response</strong></p></td></tr><tr><td style="vertical-align:top"><p>DoR &ge; 12 months, n (%)&nbsp;</p></td><td style="vertical-align:top"><p>31 (91.2%)</p></td></tr><tr><td style="vertical-align:top"><p>DoR &ge; 24 months, n (%)&nbsp;</p></td><td style="vertical-align:top"><p>26 (76.5%)</p></td></tr><tr><td style="vertical-align:top"><p>DoR &ge; 36 months, n (%)</p></td><td style="vertical-align:top"><p>21 (61.8%)</p></td></tr></tbody></table><p dir="ltr">CI &ndash; confidence interval, DoR &ndash; duration of response.</p><p dir="ltr"><sup>a</sup> Responses required confirmation at least<sup> </sup>3 months after the criteria for first partial response were met.</p><p dir="ltr"><sup>b</sup> Complete response: disappearance of the target lesion; partial response: decrease in target PN volume by &ge;&nbsp;20% compared to baseline.</p><p dir="ltr">&nbsp;</p><p dir="ltr">An independent centralized review of tumour response per REiNS criteria (data cut-off June 2018) resulted in an ORR of 44% (95% CI: 30.0, 58.7).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The median time to onset of response was 7.2&nbsp;months (range: 3.3&nbsp;months to 3.2&nbsp;years). The median (min-max) time to the maximal PN shrinkage from baseline was 15.1&nbsp;months (range: 3.3&nbsp;months to 5.2&nbsp;years). The median DoR from onset of response was not reached; at the time of data cut-off the median follow-up time was 41.3 months. The median time from treatment initiation to disease progression while on treatment was not reached.</p><p dir="ltr">At the time of data cut-off or last scan on treatment for patients who had discontinued treatment, 25&nbsp;(50%) patients remained in confirmed partial response, 1&nbsp;(2%) had unconfirmed partial responses, 12&nbsp;(24%) had stable disease and 10 (20%) had progressive disease.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Paediatric population </u></p><p dir="ltr">The European Medicines Agency has deferred the obligation to submit the results of studies with Koselugo in one or more subsets of the paediatric population in NF1 PN (see section&nbsp;4.2 for information on paediatric use).</p><p dir="ltr">&nbsp;</p><p dir="ltr">This medicinal product has been authorised under a so-called &ldquo;conditional approval&rdquo; scheme. This means that further evidence on this medicinal product is awaited. The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">At the recommended dose of 25&nbsp;mg/m<sup>2</sup> twice daily in paediatric patients (3 to &le;&nbsp;18&nbsp;years old), the geometric mean (coefficient of variation [CV%]) maximum plasma concentration (C<sub>max</sub>) was 731&nbsp;(62%) ng/mL and that of the area under the plasma drug concentration curve (AUC<sub>0‑12</sub>) following the first dose was 2009&nbsp;(35%)&nbsp;ng&middot;h/mL. Minimal accumulation of ~1.1‑fold was observed at steady state upon twice daily dosing.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In paediatric patients, at a dose level of 25&nbsp;mg/m<sup>2</sup>, selumetinib has an apparent oral clearance of 8.8&nbsp;L/h, mean apparent volume of distribution at steady state of 78&nbsp;L and mean elimination half-life of ~6.2&nbsp;hours.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Absorption</u></p><p dir="ltr">In healthy adult subjects, the mean absolute oral bioavailability of selumetinib was 62%.</p><p dir="ltr">Following oral dosing, selumetinib is rapidly absorbed, producing peak steady state plasma concentrations (t<sub>max</sub>) between 1‑1.5&nbsp;hours post-dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Effect of food </u></em></p><p dir="ltr">In separate clinical studies, in healthy adult subjects and in adult patients with advanced solid malignancies at a dose of 75&nbsp;mg, co-administration of selumetinib with a high-fat meal resulted in a mean decrease in C<sub>max</sub> of 50% and 62%, respectively, compared to fasting administration. Selumetinib mean AUC was reduced by 16% and 19%, respectively, and the time to reach maximum concentration (t<sub>max</sub>) was delayed by approximately 1.5 to 3 hours (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In healthy adult subjects at a dose of 50&nbsp;mg, co-administration of selumetinib with a low-fat meal resulted in 60% lower C<sub>max</sub> when compared to fasting administration. Selumetinib AUC was reduced by 38%, and the time to reach maximum concentration (t<sub>max</sub>) was delayed by approximately 0.9&nbsp;hours (see section&nbsp;4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">In adolescent patients with NF1 and inoperable PN treated with multiple doses of 25 mg/m<sup>2</sup> bid, co‑administration of selumetinib with a low-fat meal resulted in 24% lower C<sub>max</sub> when compared to fasting administration. Selumetinib AUC was reduced by 8%, and t<sub>max</sub> was delayed by approximately 0.57 hours (see section 4.2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">A population PK analysis including children and adolescent patients with NF1 and inoperable PN, adult patients with advanced solid malignancies and healthy adult subjects taken from 15 studies showed that concomitant administration of a low or high fat meal resulted in a mean decrease in the exposure (AUC) of selumetinib when compared to fasted administration (23.1% and 20.7%, respectively) which was not considered clinically relevant.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Distribution</u></p><p dir="ltr">The mean apparent volume of distribution at steady state of selumetinib across 20 to 30&nbsp;mg/m<sup>2</sup> ranged from 78 to 171&nbsp;L in paediatric patients, indicating moderate distribution into tissue.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>In vitro</em> plasma protein binding is 98.4% in humans. Selumetinib mostly binds to serum albumin (96.1%) than &alpha;-1 acid glycoprotein (&lt;&nbsp;35%).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Biotransformation</u></p><p dir="ltr"><em>In vitro,</em> selumetinib undergoes phase&nbsp;1 metabolic reactions including oxidation of the side chain, N‑demethylation, and loss of the side chain to form amide and acid metabolites. CYP3A4 is the predominant isoform responsible for selumetinib oxidative metabolism with CYP2C19, CYP2C9, CYP2E1 and CYP3A5 involved to a lesser extent. <em>In vitro</em> studies indicate that selumetinib also undergoes direct phase&nbsp;2 metabolic reactions to form glucuronide conjugates principally involving the enzymes UGT1A1 and UGT1A3. Glucuronidation is a significant route of elimination for selumetinib phase&nbsp;1 metabolites involving several UGT isoforms.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Following oral dosing of <sup>14</sup>C-selumetinib to healthy male subjects, unchanged selumetinib (~40% of the radioactivity) with other metabolites including glucuronide of imidazoindazole metabolite (M2; 22%), selumetinib glucuronide (M4; 7%), N-desmethyl selumetinib (M8; 3%), and N-desmethyl carboxylic acid (M11; 4%) accounted for the majority of the circulating radioactivity in human plasma. N-desmethyl selumetinib represents less than 10% of selumetinib levels in human plasma but is approximately 3 to 5&nbsp;times more potent than the parent compound, contributing to about 21% to 35% of the overall pharmacologic activity.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>Interactions</u></em></p><p dir="ltr"><em>In vitro, </em>selumetinib is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP2E1. <em>In vitro,</em> selumetinib is not an inducer of CYP1A2 and CYP2B6. Selumetinib is an inducer of CYP3A4 in vitro, this is however not expected to be clinically relevant.</p><p dir="ltr"><em><u>&nbsp;</u></em></p><p dir="ltr"><em>I</em><em>n vitro</em><em>,</em><em> </em>selumetinib inhibits UGT1A3, UGT1A4, UGT1A6 and UGT1A9 however these effects are not expected to be clinically relevant.</p><p dir="ltr"><em><u>&nbsp;</u></em></p><p dir="ltr"><em><u>Interactions with transport proteins</u></em></p><p dir="ltr">Based on<em> in vitro</em> studies, selumetinib is a substrate for BCRP and P-gp transporters but is unlikely to be subjected to clinically relevant drug interactions<em>. In vitro </em>studies suggest that selumetinib does not inhibit the breast cancer resistance protein (BCRP), P-glycoprotein (P-gp), OATP1B1, OATP1B3, OCT2, OAT1, MATE1 and MATE2K at the recommended paediatric dose. A clinically relevant effect on the pharmacokinetics of concomitantly administered substrates of OAT3 cannot be excluded.</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Elimination</u></p><p dir="ltr">In healthy adult subjects, following a single oral 75&nbsp;mg dose of radiolabelled selumetinib, 59% of the dose was recovered in faeces (19% unchanged) while 33% of the administered dose (&lt;&nbsp;1% as parent) was found in urine by 9&nbsp;days of sample collection.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Special populations</u></p><p dir="ltr"><em><u>Renal impairment</u></em></p><p dir="ltr">The exposure of 50&nbsp;mg oral selumetinib was investigated in adult subjects with normal renal function (n&nbsp;=&nbsp;11) and subjects with ESRD (n&nbsp;=&nbsp;12). The ESRD group showed 16% and 28% lower C<sub>max</sub> and AUC, respectively, with the fraction of unbound selumetinib being 35% higher in ESRD subjects. As a result, the unbound C<sub>max</sub> and AUC ratios were 0.97 and 1.13 in the ESRD group when compared to the group with normal renal function. A small increase, approximately 20% AUC, in the N-desmethyl metabolite to parent ratio was detected in the ESRD group when compared to the normal group. As exposure in ESRD subjects was similar to those with normal renal function, investigations in mild, moderate and severe renally impaired subjects were not performed. Renal impairment is expected to have no meaningful influence on the exposure of selumetinib (see section&nbsp;4.2).</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>Hepatic impairment</u></em></p><p dir="ltr">Adult subjects with normal hepatic function (n&nbsp;=&nbsp;8) and mild hepatic impairment (Child-Pugh&nbsp;A, n&nbsp;=&nbsp;8) were dosed with 50&nbsp;mg selumetinib, subjects with moderate hepatic impairment (Child-Pugh&nbsp;B, n&nbsp;=&nbsp;8) were administered a 50&nbsp;or 25&nbsp;mg dose, and subjects with severe hepatic impairment (Child‑Pugh&nbsp;C, n&nbsp;=&nbsp;8) were administered a 20&nbsp;mg dose. Selumetinib total dose normalised AUC and unbound AUC were 86% and 69% respectively, in mild hepatic impairment patients, compared to the AUC values for subjects with normal hepatic function. Selumetinib exposure (AUC) was higher in patients with moderate (Child-Pugh&nbsp;B) and severe (Child-Pugh&nbsp;C) hepatic impairment; the total AUC and unbound AUC values were 159% and 141% (Child-Pugh&nbsp;B) and 157% and 317% (Child-Pugh&nbsp;C), respectively, of subjects with normal hepatic function (see section&nbsp;4.2). There was a trend of lower protein binding in subjects with severe hepatic impairment although the protein binding remained &gt;&nbsp;99% (see section&nbsp;4.3).</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>Ethnicity</u></em></p><p dir="ltr">Following a single-dose, selumetinib exposure appears to be higher in Japanese, non-Japanese-Asian and Indian healthy adult subjects compared to Western adult subjects, however, there is considerable overlap with Western subjects when corrected for body weight or BSA (see section&nbsp;4.2).<s> </s></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>Adult patients (&gt;&nbsp;18&nbsp;years old)</u></em></p><p dir="ltr">The PK parameters in adult healthy subjects and adult patients with advanced solid malignancies, are similar to those in paediatric patients (3&nbsp;to&nbsp;&le; 18&nbsp;years old) with NF1.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In adult patients, C<sub>max</sub> and AUC increased dose proportionally over a 25&nbsp;mg to 100&nbsp;mg dose range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Genotoxicity</u></p><p>Selumetinib was positive in the mouse micronucleus study via an aneugenic mode of action. The free mean exposure (C<sub>max</sub>) at the no observed effect level (NOEL) was approximately 27‑times greater than clinical free exposure at the maximum recommended human dose (MRHD) of 25&nbsp;mg/m<sup>2</sup>.</p><p>&nbsp;</p><p><u>Carcinogenicity</u></p><p>Selumetinib was not carcinogenic in rats or transgenic mice.</p><p>&nbsp;</p><p><u>Repeat-dose toxicity </u></p><p>In repeat-dose toxicity studies in mice, rats and monkeys, the main effects seen after Selumetinib exposure were in the skin, GI tract and bones. Scabs associated with microscopic erosions and ulceration at a free exposure similar to the clinical exposure (free AUC) at the MRHD were seen in rats. Inflammatory and ulcerative GI tract findings associated with secondary changes in the liver and lymphoreticular system at free exposures approximately 28&nbsp;times the clinical free exposure at the MRHD were observed in mice. Growth plate (physeal) dysplasia was seen in male rats dosed for up to 3&nbsp;months with Selumetinib at a free exposure 11&nbsp;times the clinical free exposure at the MRHD. GI&nbsp;findings showed evidence of reversibility following a recovery period. Reversibility for skin toxicities and physeal dysplasia was not evaluated. Vascular engorgement of the corpus cavernosum of the bulbocavernosus muscle were observed in male mice in a 26‑week study at a dose of 40&nbsp;mg/kg/day (28&nbsp;times the free AUC in humans at the MRHD) leading to significant urinary tract obstruction as well as inflammation and luminal haemorrhage of the urethra leading to early death in male mice.</p><p>&nbsp;</p><p><u>Reproductive toxicology</u></p><p>Developmental and reproduction toxicity studies were conducted in mice. Fertility was not affected in male mice at up to 40 mg/kg/day (corresponding to 22‑fold the free AUC in humans at the MRHD). In females, mating performance and fertility were not affected at up to 75&nbsp;mg/kg/day, but a reversible decrease in the number of live fetuses was observed at this dose level; the NOAEL for effects on reproductive performance was 5&nbsp;mg/kg/day (approximately 3.5‑fold the free<strong> </strong>AUC in humans at the MRHD). A treatment-related increase in the incidence of external malformations (open eye, cleft palate) was reported in absence of maternal toxicity in embryo-fetal development studies at &gt;&nbsp;5&nbsp;mg/kg/day, and in the pre- and post-natal development study at &ge;&nbsp;1&nbsp;mg/kg/day (corresponding to 0.4‑fold the free C<sub>max </sub>in humans at the MRHD). The other treatment related effects observed at non-maternotoxic dose levels in these studies consisted of embryo-lethality and decreased fetal weight at &ge;&nbsp;25 mg/kg/day (corresponding to 22‑fold the free AUC in humans at the MRHD), reductions in post-natal pup growth and at weaning a lower number of pups met the pupil constriction criterion at 15&nbsp;mg/kg/day (corresponding to 3.6‑fold the free C<sub>max</sub> in humans at the MRHD). Selumetinib and its active metabolite were excreted in the milk of lactating mice at concentrations approximately the same as those in plasma.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Capsule content</u></p><p dir="ltr">Tocofersolan (Vitamin E polyethylene glycol succinate /D &alpha;-tocopheryl polyethylene glycol succinate).</p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr"><u>Capsule shell </u></p><p dir="ltr"><em><u>Koselugo 10 mg hard capsules</u></em></p><p dir="ltr">Hypromellose (E464)</p><p dir="ltr">Carrageenan (E407)</p><p dir="ltr">Potassium chloride (E508)</p><p dir="ltr">Titanium dioxide (E171)</p><p dir="ltr">Carnauba wax (E903)</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Koselugo 25 mg hard capsules</u></em></p><p dir="ltr">Hypromellose (E464)</p><p dir="ltr">Carrageenan (E407)</p><p dir="ltr">Potassium chloride (E508)</p><p dir="ltr">Titanium dioxide (E171)</p><p dir="ltr">Indigo carmine aluminium lake (E132)</p><p dir="ltr">Iron oxide yellow (E172)</p><p dir="ltr">Carnauba wax (E903)</p><p dir="ltr">Maize starch</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Printing ink</u></p><p dir="ltr"><em><u>Koselugo 10 mg hard capsules</u></em></p><p dir="ltr">Shellac glaze, standard (E904)</p><p dir="ltr">Iron oxide black (E172)</p><p dir="ltr">Propylene glycol (E1520)</p><p dir="ltr">Ammonium hydroxide (E527)</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><em><u>Koselugo 25 mg hard capsules</u></em></p><p dir="ltr">Iron oxide red (E172)</p><p dir="ltr">Iron oxide yellow (E172)</p><p dir="ltr">Indigo carmine aluminium lake (E132)</p><p dir="ltr">Carnauba wax (E903)</p><p dir="ltr">Shellac, standard (E904)</p><p dir="ltr">Glyceryl mono-oleate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 Months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Do not store above 30&nbsp;&deg;C.</p><p dir="ltr">Store in the original bottle in order to protect from moisture and light.</p><p dir="ltr">Keep the bottle tightly closed.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Koselugo 10 mg hard capsules</u></p><p dir="ltr">High-density polyethylene (HDPE) plastic bottle with white child-resistant polypropylene closure.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Koselugo 25 mg hard capsules</u></p><p dir="ltr">High-density polyethylene (HDPE) plastic bottle with blue child-resistant polypropylene closure.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Each bottle contains 60&nbsp;hard capsules and a silica gel desiccant. Each carton contains one bottle</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Patients should be instructed not to remove the desiccant from the bottle.</p><p dir="ltr">Any unused medicinal product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AstraZeneca AB
SE 151 85 Södertälje
Sweden

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nov 2023

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>